AUGUSTA, Maine — Maine stands to get about $43,000 as part of a $34 million settlement that the maker of an epilepsy treatment drug has agreed to pay for marketing the drug in violation of U.S. drug laws.
The U.S. subsidiary of Belgian manufacturer UCB pleaded guilty Thursday in federal court in Washington to a misdemeanor in connection with the misbranding. The company will pay a criminal fine of more than $7 million, forfeit $1 million in assets and pay nearly $26 million to resolve civil claims that it promoted off-label uses of the drug, including migraines, pain, mood disorders and anxiety.
As part of the civil settlement, nearly $10 million will go to Medicaid programs in Maine and other states.
Maine Attorney General William Schneider said UCB put “profit ahead of patients.”
Copy the Story LinkSend questions/comments to the editors.
Success. Please wait for the page to reload. If the page does not reload within 5 seconds, please refresh the page.
Enter your email and password to access comments.
Hi, to comment on stories you must . This profile is in addition to your subscription and website login.
Already have a commenting profile? .
Invalid username/password.
Please check your email to confirm and complete your registration.
Only subscribers are eligible to post comments. Please subscribe or login first for digital access. Here’s why.
Use the form below to reset your password. When you've submitted your account email, we will send an email with a reset code.